Eagle Pharmaceuticals: Q2 Earnings Snapshot
Eagle Pharmaceuticals: Q1 Earnings Snapshot
Eagle Pharmaceuticals: Q4 Earnings Snapshot
Eagle Pharmaceuticals: Q3 Earnings Snapshot
EGRX earnings call for the period ending June 30, 2022.
• Q2 2022 net loss was $(0.74) per basic and diluted share and adjusted non-GAAP net income was $1.58 per basic and $1.56 per diluted share • Total...
-- ENA-001 is currently in development for: post-operative respiratory depression, community drug overdose, and Apnea of Prematurity -- -- Approval for...
WOODCLIFF LAKE, N.J., July 18, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced the...
Adds two U.S. Food and Drug Administration (“FDA”) approved new chemical entities with strong patent protectionBARHEMSYS® (amisulpride for injection) and...
-- Submission seeks approval for landiolol for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial...